Hospira Files Two Petitions for Inter Partes Review of Genentech’s Trastuzumab-Related Patents


Hospira filed two petitions for inter partes review of Genentech’s U.S. Patent 7,371,379 (IPR2017-00805) and U.S. Patent 6,627,196 (IPR2017-00804).  According to the petitions, these patents are directed to methods of treating certain cancers with trastuzumab, sold under the name Herceptin®.  These petitions follow closely on the heels of three petitions that Hospira filed on two other Genentech patents related to trastzumab, as we previously reported.

The petitions for these two IPRs and other important IPR filings on biologics are posted to our IPR tracker page.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.